Stem-cell therapy for bronchopulmonary dysplasia

Collins (2020) Stem-cell therapy for bronchopulmonary dysplasia Curr Opin Pediatr (IF: 3.6) 32(2) 210-215

Abstract

Clinical trials of mesenchymal stem/stromal cell (MSC) therapy for bronchopulmonary dysplasia (BPD) are underway. A thorough understanding of the preclinical work that underpins these trials is critical for neonatal practitioners to properly evaluate them.Significant progress has been made in understanding that MSCs have anti-inflammatory and proangiogenic effects, and that these can be mediated by the noncellular exosome fraction of MSCs.In rodent hyperoxia models of BPD, MSCs have a proangiogenic effect mediated largely by vascular endothelial growth factor and shift the balance of endogenous lung cells from a proinflammatory to a prohealing phenotype. MSC-derived exosomes can recapitulate these effects.

Links

http://www.ncbi.nlm.nih.gov/pubmed/31833951
http://dx.doi.org/10.1097/MOP.0000000000000862

Similar articles

Tools